Repositorio de producción científica de la Universidad de Sevilla

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study

 

Advanced Search
 
Opened Access Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study
Cites

Show item statistics
Icon
Export to
Author: Fernández, Oscar
Izquierdo Ayuso, Guillermo
Fernández Montesinos, Rafael
Pozo Pérez, David
Leyva, Laura
Department: Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología
Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica
Date: 2018
Published in: PLoS ONE, 13 (5), e0195891-1-e0195891-14.
Document type: Article
Abstract: Background Currently available treatments for secondary progressive multiple sclerosis(SPMS) have limited efficacy and/or safety concerns. Adipose-mesenchymal derived stem cells(AdMSCs) represent a promising option and can be readily obtained usi...
[See more]
Cite: Fernández, O., Izquierdo Ayuso, G., Fernández Montesinos, R., Pozo Pérez, D. y Leyva, L. (2018). Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS ONE, 13 (5), e0195891-1-e0195891-14.
Size: 814.3Kb
Format: PDF

URI: https://hdl.handle.net/11441/78158

DOI: 10.1371/journal.pone.0195891

See editor´s version

This work is under a Creative Commons License: 
Attribution-NonCommercial-NoDerivatives 4.0 Internacional

This item appears in the following Collection(s)